scholarly article | Q13442814 |
P50 | author | Bernard Moss | Q822617 |
Rama Rao Amara | Q88444844 | ||
Bali Pulendran | Q88744806 | ||
Paul Spearman | Q92752230 | ||
Sudhir Pai Kasturi | Q96176484 | ||
Rafiq Nabi | Q117274385 | ||
David C. Montefiori | Q63302725 | ||
Celia C LaBranche | Q63422835 | ||
Georgia D. Tomaras | Q63663866 | ||
Pamela A Kozlowski | Q88438362 | ||
Sailaja Gangadhara | Q88444841 | ||
P2093 | author name string | Xiaoying Shen | |
Pradeep B J Reddy | |||
Xuemin Chen | |||
Smita S Iyer | |||
Blandine Victor | |||
Michael J Sabula | |||
P2860 | cites work | Immune correlates of vaccine protection against HIV-1 acquisition | Q26778573 |
A brief history of the global effort to develop a preventive HIV vaccine | Q26851165 | ||
Mucosal B Cells Are Associated with Delayed SIV Acquisition in Vaccinated Female but Not Male Rhesus Macaques Following SIVmac251 Rectal Challenge | Q27318151 | ||
Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes | Q28271300 | ||
HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers | Q28647225 | ||
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand | Q29547531 | ||
Ending the global HIV/AIDS pandemic: the critical role of an HIV vaccine. | Q30365998 | ||
Programming the magnitude and persistence of antibody responses with innate immunity | Q30400144 | ||
A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples | Q30498394 | ||
Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial | Q30532861 | ||
A computational framework for the analysis of peptide microarray antibody binding data with application to HIV vaccine profiling | Q30648718 | ||
Dendritic cells are preferentially targeted among hematolymphocytes by Modified Vaccinia Virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo | Q33328336 | ||
Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles | Q33813145 | ||
Why HIV virions have low numbers of envelope spikes: implications for vaccine development | Q34016070 | ||
CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge | Q34059531 | ||
Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection | Q34402934 | ||
Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection | Q34444625 | ||
Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251. | Q34462107 | ||
Common features of mucosal and peripheral antibody responses elicited by candidate HIV-1 vaccines in rhesus monkeys | Q34594754 | ||
Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine | Q34619904 | ||
Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles | Q34772727 | ||
Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia | Q34848486 | ||
Interplay between modified vaccinia virus Ankara and dendritic cells: phenotypic and functional maturation of bystander dendritic cells. | Q34982651 | ||
Antibody to the gp120 V1/V2 loops and CD4+ and CD8+ T cell responses in protection from SIVmac251 vaginal acquisition and persistent viremia | Q35105449 | ||
Codelivery of Envelope Protein in Alum with MVA Vaccine Induces CXCR3-Biased CXCR5+ and CXCR5- CD4 T Cell Responses in Rhesus Macaques | Q35864543 | ||
Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates | Q35914306 | ||
Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccine | Q36141586 | ||
GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine | Q36407775 | ||
Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. | Q36489415 | ||
Analysis of simian immunodeficiency virus sequence variation in tissues of rhesus macaques with simian AIDS | Q36654291 | ||
Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. | Q36895518 | ||
Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys | Q37355237 | ||
HIV-specific antibody-dependent phagocytosis matures during HIV infection. | Q38873975 | ||
Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. | Q39874667 | ||
Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays | Q39988991 | ||
Nasal DNA-MVA SIV vaccination provides more significant protection from progression to AIDS than a similar intramuscular vaccination. | Q51890555 | ||
Immunogenicity in macaques of the clinical product for a clade B DNA/MVA HIV vaccine: elicitation of IFN-gamma, IL-2, and TNF-alpha coproducing CD4 and CD8 T cells. | Q51968415 | ||
Modified wick method using Weck-Cel sponges for collection of human rectal secretions and analysis of mucosal HIV antibody | Q73030181 | ||
P433 | issue | 19 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Simian immunodeficiency virus | Q1890246 |
Vaccinia virus | Q1986297 | ||
P304 | page(s) | 8842-8854 | |
P577 | publication date | 2016-07-27 | |
P1433 | published in | Journal of Virology | Q1251128 |
P1476 | title | Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques | |
P478 | volume | 90 |
Q89790335 | A bivalent, spherical virus-like particle vaccine enhances breadth of immune responses against pathogenic Ebola viruses in rhesus macaques |
Q47296227 | A trimeric HIV-1 envelope gp120 immunogen induces potent and broad anti-V1V2 loop antibodies against HIV-1 in rabbits and rhesus macaques |
Q56517308 | Control of Heterologous Simian Immunodeficiency Virus SIV Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in Macaques |
Q37628515 | Dendritic Cell Targeting Effectively Boosts T Cell Responses Elicited by an HIV Multiepitope DNA Vaccine |
Q33865785 | Differences in serum IgA responses to HIV-1 gp41 in elite controllers compared to viral suppressors on highly active antiretroviral therapy |
Q63246465 | HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge |
Q92152909 | Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Ch |
Q37633417 | Native-like Env trimers as a platform for HIV-1 vaccine design |
Q57282350 | Oral co-administration of an intramuscular DNA/ Modified Vaccinia Ankara vaccine for simian immunodeficiency virus is associated with better control of infection in orally exposed infant macaques |
Q91890041 | Rectal Microbiome Composition Correlates with Humoral Immunity to HIV-1 in Vaccinated Rhesus Macaques |
Q40116011 | Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice |
Q94562592 | T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers |
Q38621582 | The Impact of Poxvirus Vector Priming, Protein Co-Administration, and Vaccine Intervals on HIV gp120 Vaccine-Elicited Antibody Magnitude and Function in Infant Macaques |
Q47276928 | Vaccination with Combination DNA and Virus-Like Particles Enhances Humoral and Cellular Immune Responses upon Boost with Recombinant Modified Vaccinia Virus Ankara Expressing Human Immunodeficiency Virus Envelope Proteins |
Q90226623 | Viral Vectors for the Induction of Broadly Neutralizing Antibodies against HIV |
Q52655238 | Virus-Like Particle, Liposome, and Polymeric Particle-Based Vaccines against HIV-1. |
Search more.